JP2006176498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006176498A5 JP2006176498A5 JP2005335154A JP2005335154A JP2006176498A5 JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5 JP 2005335154 A JP2005335154 A JP 2005335154A JP 2005335154 A JP2005335154 A JP 2005335154A JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hmg
- coa reductase
- reductase inhibitor
- ubidecarenone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005335154A JP4896501B2 (en) | 2004-11-26 | 2005-11-21 | Pharmaceutical composition having blood free fatty acid lowering action |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004341493 | 2004-11-26 | ||
JP2004341493 | 2004-11-26 | ||
JP2005335154A JP4896501B2 (en) | 2004-11-26 | 2005-11-21 | Pharmaceutical composition having blood free fatty acid lowering action |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006176498A JP2006176498A (en) | 2006-07-06 |
JP2006176498A5 true JP2006176498A5 (en) | 2009-01-29 |
JP4896501B2 JP4896501B2 (en) | 2012-03-14 |
Family
ID=36730936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005335154A Expired - Fee Related JP4896501B2 (en) | 2004-11-26 | 2005-11-21 | Pharmaceutical composition having blood free fatty acid lowering action |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4896501B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012096998A (en) * | 2009-02-27 | 2012-05-24 | Kowa Co | Stable capsule preparation and method for producing the same |
TWI636783B (en) * | 2012-04-18 | 2018-10-01 | 友霖生技醫藥股份有限公司 | Stable formulations of pitavastatin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2007983C (en) * | 1989-01-18 | 1996-12-10 | Michael S. Brown | Coenzyme q10 with hmg-coa reductase inhibitors |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
AUPR177300A0 (en) * | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
JP2003081873A (en) * | 2001-06-28 | 2003-03-19 | Takeda Chem Ind Ltd | Prophylactic or therapeutic agent for organ functional disorder and organ insufficiency |
WO2003090671A2 (en) * | 2002-04-23 | 2003-11-06 | Nutrition 21, Inc. | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
-
2005
- 2005-11-21 JP JP2005335154A patent/JP4896501B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2022100434A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING EPA AND CARDIOVASCULAR DRUG AND METHODS OF THEIR APPLICATION | |
JP2010047616A5 (en) | ||
WO2008045170A3 (en) | Statin and omega-3 fatty acids for reduction of apo-b levels | |
JP2015503588A5 (en) | ||
JP2007523049A5 (en) | ||
JP2008509132A5 (en) | ||
JP2004537553A5 (en) | ||
EA200970359A1 (en) | STATIN AND OMEGA-3 FATTY ACIDS TO REDUCE ARO-B LEVELS | |
JP2007238598A5 (en) | ||
AR076835A1 (en) | COMPOSITIONS OF ORAL DISINTEGRATION TABLETS THAT INCLUDE COMBINATIONS OF DRUGS IN ELEVATED AND REDUCED DOSE. METHOD. | |
NZ600720A (en) | A Seamless Capsule For A Liquid Pharmaceutical Composition | |
NZ603207A (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
JP2007277267A5 (en) | ||
JP2008515980A5 (en) | ||
NO20065152L (en) | Sustained-release formulation for oral administration of HMG-COA reductase inhibitor, and its precursor for its preparation | |
WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
WO2018064654A1 (en) | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof | |
JP2005511619A5 (en) | ||
JP2006176498A5 (en) | ||
JP2013536408A5 (en) | ||
JP2010505866A5 (en) | ||
JP2008063322A5 (en) | ||
WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
WO2013073884A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
AR048668A1 (en) | HYPOOCOLESTEROLEMIANT COMPOSITIONS AND PROCEDURE TO PREPARE THEM |